Werewolf Therapeutics, Inc. — Investor Relations & Filings
Werewolf Therapeutics, Inc. is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company utilizes its proprietary PREDATOR® protein engineering platform to create a novel class of conditionally activated proinflammatory immune modulators, known as INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become selectively activated within the tumor microenvironment. This approach aims to generate a potent, localized anti-tumor immune response while minimizing the systemic side effects associated with conventional immunotherapies. The company's pipeline includes clinical-stage candidates such as WTX-124 and WTX-330.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-K - Werewolf Therapeutics, Inc. (0001785530) (Filer) | 2026-03-27 | English | |
| 8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer) | 2026-03-27 | English | |
| 8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer) | 2026-02-24 | English | |
| 8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer) | 2026-02-13 | English | |
| SCHEDULE 13G/A Filing | 2026-02-11 | English | |
| 8-K Filing | 2026-02-06 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 33058433 | 10-K - Werewolf Therapeutics, Inc. (0001785530) (Filer) | 2026-03-27 | English | ||
| 33058414 | 8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer) | 2026-03-27 | English | ||
| 32898233 | 8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer) | 2026-02-24 | English | ||
| 32898234 | 8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer) | 2026-02-13 | English | ||
| 31705258 | SCHEDULE 13G/A Filing | 2026-02-11 | English | ||
| 31705271 | 8-K Filing | 2026-02-06 | English | ||
| 13198047 | Director's Dealing 2026 | 2026-01-20 | English | ||
| 13198048 | Major Shareholding Notification 2026 | 2026-01-16 | English | ||
| 13198049 | Director's Dealing 2026 | 2026-01-15 | English | ||
| 13198050 | Director's Dealing 2026 | 2026-01-12 | English | ||
| 13198051 | Director's Dealing 2026 | 2026-01-07 | English | ||
| 13198052 | Regulatory Filings 2026 | 2026-01-06 | English | ||
| 13198053 | Regulatory Filings 2026 | 2026-01-06 | English | ||
| 13198054 | Regulatory Filings 2026 | 2026-01-06 | English | ||
| 13198055 | Regulatory Filings 2026 | 2026-01-06 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Chongqing Zhifei Biological Products Co.,Ltd.
Develops and distributes vaccines and biological products v…
|
300122 | CN | Manufacturing |
|
CHOONG ANG VACCINE LABORATORY
Develops and manufactures vaccines, pharmaceuticals, and fe…
|
072020 | KR | Manufacturing |
|
CHOSA Oncology AB
Develops diagnostics and therapeutics for platinum-based ch…
|
CHOSA | SE | Manufacturing |
|
CHUGAI PHARMACEUTICAL CO., LTD.
A research-driven pharmaceutical company developing innovat…
|
4519 | JP | Manufacturing |
|
CHUKYOIYAKUHIN CO.,LTD.
Offers health products and pharmaceuticals via a direct-to-…
|
4558 | JP | Manufacturing |
|
Cian Healthcare Limited
WHO-GMP certified manufacturer of diverse healthcare produc…
|
542678 | IN | Manufacturing |
|
Cidara Therapeutics, Inc.
Develops targeted immunotherapies and anti-infectives for s…
|
CDTX | US | Manufacturing |
|
CILO CYBIN HOLDINGS LIMITED
Vertically integrated medical cannabis company with GACP cu…
|
CCCE | ZA | Manufacturing |
|
Cinclus Pharma Holding AB
Clinical-stage pharma company developing a PCAB for gastric…
|
CINPHA | SE | Manufacturing |
|
Cingulate Inc.
A clinical-stage biopharma firm developing treatments for A…
|
CING | US | Manufacturing |
Werewolf Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34192/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34192 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34192 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34192 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34192}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Werewolf Therapeutics, Inc. (id: 34192)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.